How could it be an advantage to take away the inactive component of a chiral compound, but retain the same amount of the active component?

On a theoretical basis, a single enantiomer might provide superior therapy because it:

• reduces the dose given, and thereby reduces the metabolic load
• reduces interpatient variability in metabolism/response
• simplifies dose–response relationships
• removes an inactive/undesirable ‘impurity’